Core Insights - BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI, aiming for approval in the at-home treatment of acute agitation associated with bipolar disorders and schizophrenia, with potential approval as early as the end of 2026 [1][2] Company Developments - The company reported a net revenue of $256,000 for Q4 2025, down from $366,000 in Q4 2024, and a full-year revenue of $642,000 for 2025, compared to $2.3 million in 2024 [7] - Research and Development (R&D) expenses increased to $6.7 million in Q4 2025 from $5.9 million in Q4 2024, primarily due to clinical trial expenses related to the SERENITY At-Home pivotal Phase 3 trial [9] - Selling, General and Administrative (SG&A) expenses decreased to $3.8 million in Q4 2025 from $4.1 million in Q4 2024, and for the full year, SG&A expenses were $20.5 million, down from $34.5 million in 2024 [10][11] Market Opportunity - A third-party market assessment indicates a significant total addressable market for IGALMI in the at-home setting, with up to 86 million addressable annual episodes that may require treatment [5] - The company is advancing its commercial strategy and launch plans for IGALMI based on insights from the market assessment [1][5] Clinical Programs - The SERENITY At-Home Phase 3 trial is designed to evaluate the safety of a 120-mcg dose of BXCL501 for treating agitation associated with bipolar disorders or schizophrenia in the at-home setting [24] - The TRANQUILITY In-Care Phase 3 trial aims to assess the efficacy and safety of a 60-mcg dose of BXCL501 for agitation associated with Alzheimer's dementia in care settings [25] Financial Performance - The company reported an operating loss of $10.3 million and a net loss of $12.5 million for Q4 2025, compared to an operating loss of $10.5 million and a net loss of $10.9 million for Q4 2024 [12] - For the full year 2025, the operating loss was $50.5 million, and the net loss was $69.9 million, compared to an operating loss of $67.2 million and a net loss of $59.6 million for 2024 [13] Cash Position - As of December 31, 2025, the company had cash and cash equivalents totaling $28.8 million, down from $29.9 million at the end of 2024 [13]

Core Insights - BioXcel Therapeutics Inc. (NASDAQ:BTAI) shares have declined following a previous rally due to positive drug development news, specifically regarding BXCL501 for opioid withdrawal treatment [1][5] Group 1: Drug Development and Clinical Trials - BXCL501 has shown promise in a Phase 2 study for treating opioid withdrawal symptoms, potentially being as effective or superior to BioCorRx Pharmaceuticals Inc.'s lofexidine [2] - Patients receiving BXCL501 experienced over a 30% reduction in withdrawal symptoms compared to a placebo, with significant improvements noted on days three and four of the trial [2][3] - The data suggests BXCL501's versatility as a treatment option, indicating potential applicability for acute agitation associated with bipolar disorder and schizophrenia [3] Group 2: Stock Performance and Technical Analysis - The stock is currently trading 3.9% below its 20-day simple moving average (SMA) and 17.9% below its 100-day SMA, indicating challenges in gaining traction in the short to medium term [4] - Over the past 12 months, shares have decreased approximately 41.24%, positioning them closer to their 52-week lows than highs [4] - The Relative Strength Index (RSI) is at 46.86, suggesting the stock is in neutral territory, while the MACD indicates bullish momentum despite the overall bearish trend [4][5]

Core Insights - BioXcel Therapeutics Inc. shares have increased in premarket trading following positive results from a Phase 2 study of BXCL501 for opioid withdrawal symptoms [1] Study Results - The Phase 2 trial, conducted by Columbia University, indicated that BXCL501 may be as effective or superior to BioCorRx Pharmaceuticals' lofexidine (Lucemyra) in reducing opioid withdrawal symptoms during methadone taper, with a more convenient dosing regimen [2] - Patients receiving BXCL501 240 µg BID experienced over a 30% reduction in Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) scores, with peak symptom improvement noted on days 3 and 4 [3] - The reduction in withdrawal symptoms with BXCL501 was numerically greater than that observed with lofexidine 0.54 mg administered four times daily, and BXCL501 showed a favorable tolerability profile compared to lofexidine [3] Product Pipeline - BXCL501 is positioned as a "pipeline within a product," with potential applications across various indications, including acute agitation associated with bipolar disorder and schizophrenia [4] - In September 2025, BioXcel Therapeutics released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, demonstrating continued effects and consistent benefits with repeat dosing of BXCL501 [4] Technical Analysis - The stock is trading 1.5% above its 20-day simple moving average (SMA) and 5.2% below its 100-day SMA, indicating short-term strength but longer-term challenges [5] - Over the past 12 months, shares have decreased approximately 76% and are closer to their 52-week lows than highs [5] - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [6] Price Action - BioXcel Therapeutics shares rose 17.58% to $1.94 during premarket trading, with key resistance at $2.00 and key support at $1.50 [7]

Core Insights - BXCL501 has shown clinical benefits and a favorable tolerability profile for treating opioid withdrawal symptoms, supporting its potential future development in this area [1][2][3] Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [10] - The company is focused on re-innovating existing approved drugs and leveraging big data and machine learning to identify new therapeutic indications [10] Study Findings - The Phase 2 trial indicated that BXCL501 may be as effective as or superior to lofexidine for reducing opioid withdrawal symptoms during methadone taper, with a more convenient dosing regimen [3][4] - BXCL501 demonstrated lower rates of cardiovascular effects compared to lofexidine, particularly in orthostatic hypotension (18% for BXCL501 vs 50% for lofexidine, p<0.05) [3] - Patients receiving BXCL501 240 µg experienced over a 30% reduction in withdrawal symptoms as measured by the Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) [8] Market Context - Opioid use disorder (OUD) is a significant global health crisis, affecting approximately 5.9 million adults in the U.S. and an estimated 36 to 61 million people worldwide [9] - Despite the high prevalence of OUD, only about 25% of individuals with substance use disorders receive specialized treatment, indicating a substantial treatment gap [9] Product Profile - BXCL501 is an investigational orally dissolving film formulation of dexmedetomidine, designed for the acute treatment of agitation associated with various conditions, including opioid withdrawal [11] - The product has been granted Breakthrough Therapy designation by the FDA for certain indications, highlighting its potential as a safe and effective treatment option [11]

Core Insights - The discussion focuses on the urgent need for treatments addressing acute agitation episodes in Alzheimer's dementia, highlighting a significant gap in current FDA-approved options [3]. Company Commitment - BioXcel Therapeutics is dedicated to advancing innovation in areas of unmet medical need, specifically targeting the acute treatment of agitation in Alzheimer's dementia with its product BXCL501 [4]. - BXCL501 has shown promising results in a Phase III pivotal study, being well tolerated and meeting its primary efficacy endpoint [4]. Industry Context - There are currently no FDA-approved treatments specifically for acute agitation episodes in Alzheimer's dementia, indicating a critical need for effective solutions for patients, caregivers, and clinicians [3].

BioXcel Therapeutics KOL Virtual Roundtable Summary Company Overview - **Company**: BioXcel Therapeutics (NasdaqCM: BTAI) - **Focus**: Development of BXCL501 for the treatment of acute agitation episodes in Alzheimer's dementia Key Industry Insights - **Alzheimer's Agitation**: There are currently no FDA-approved treatments specifically for acute agitation episodes in Alzheimer's dementia, highlighting a significant gap in care [2][11][93] - **Demographic Trends**: The Alzheimer's population is expected to double in the coming decades, with over 7 million individuals currently affected, leading to increased neuropsychiatric issues, particularly agitation [20][21] Core Points Discussed - **BXCL501 Development**: BXCL501 has shown to be well-tolerated and met its primary efficacy endpoint in a Phase 3 pivotal study for treating acute agitation in Alzheimer's dementia [3] - **Current Treatment Landscape**: Existing treatments primarily address chronic agitation, with off-label use of antipsychotics and sedatives being common, which can lead to increased risks such as sedation and falls [10][21][22][34] - **Need for Rapid Action**: BXCL501 is designed to provide rapid control of agitation, with effects seen within minutes, contrasting with existing treatments that may take days to titrate [22][23][49] Additional Important Insights - **Impact on Caregivers**: The unpredictability of agitation episodes significantly affects the quality of life for both patients and caregivers, necessitating effective management solutions [29][82] - **Potential for Home Use**: There are plans for at-home studies to evaluate the safety and efficacy of BXCL501 in non-professional settings, which could ease the burden on caregivers [47][48] - **Safety Profile**: BXCL501 has a favorable safety profile, with mild side effects reported in clinical trials, making it a viable option for older adults [49][50][56] - **Administration Method**: The sublingual film formulation of BXCL501 is seen as advantageous compared to injections, which can be distressing for patients [68][70] Market Opportunity - **Care Settings**: BXCL501 could be beneficial in various settings, including home care, assisted living, and skilled nursing facilities, helping to maintain patient independence and reduce the need for institutionalization [82][85] - **Cost Implications**: Effective management of acute agitation could potentially reduce healthcare costs associated with emergency room visits and hospitalizations [19][22][67] Conclusion - **Commitment to Innovation**: BioXcel Therapeutics is dedicated to addressing the unmet needs in the treatment of acute agitation in Alzheimer's dementia, with BXCL501 positioned as a promising solution [2][93]

Core Insights - The discussion will focus on the high unmet need and lack of FDA-approved treatment options for acute agitation episodes in Alzheimer's dementia, affecting approximately 100 million episodes annually [1][2]. Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [6]. - The company is advancing preparations for the TRANQUILITY In-Care Phase 3 trial, which is a double-blind, placebo-controlled study evaluating BXCL501 for treating acute agitation episodes in Alzheimer's dementia [4][9]. Product Information - BXCL501 is a late-stage product candidate being evaluated for acute agitation episodes in Alzheimer's dementia, with no current FDA-approved therapies for this condition [3][8]. - BXCL501 has received Breakthrough Therapy designation from the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for agitation associated with schizophrenia and bipolar disorders [8]. Clinical Trial Details - The TRANQUILITY In-Care trial aims to enroll approximately 200 patients aged 55 and older with mild to severe dementia, assessing the efficacy and safety of a 60 mcg dose of BXCL501 over a 12-week period [9]. - The primary endpoint of the trial is a change from baseline in the Positive and Negative Syndrome Scale-Excitatory Component total score at two hours post-first dose [9]. Event Information - A virtual key opinion leader (KOL) roundtable will be held on February 27, 2026, to discuss acute agitation episodes in Alzheimer's dementia and the potential role of BXCL501 [1][2][4]. - The event will be moderated by Anjalee Khemlani, an award-winning healthcare journalist [4]. Expert Panel - The roundtable will feature medical professionals specializing in geriatric psychiatry and Alzheimer's care, including George T. Grossberg, MD, and Anton P. Porsteinsson, MD [7].

Core Insights - BioXcel Therapeutics has completed an updated market opportunity assessment for IGALMI, indicating a larger than expected total addressable market for the treatment of acute agitation associated with bipolar disorders or schizophrenia in the at-home setting [1][2] - The assessment is based on the SERENITY At-Home clinical study and aims to inform the company's launch planning activities for IGALMI [1][3] Market Opportunity Assessment - The assessment involved interviews with 15 prescribers and 5 payers, along with survey responses from 180 prescribers, to gauge interest and potential market size for IGALMI [2] - Approximately 2.3 million treated bipolar disorder and schizophrenia patients in the U.S. experience frequent episodes of acute agitation at home, with up to 1.8 million potentially eligible for IGALMI treatment [5] - This translates to an estimated 86 million addressable annual episodes requiring treatment, a significant increase from previous estimates of 57-77 million [5] Prescriber and Payer Insights - Prescribers reported a moderate to high unmet need for at-home treatment options, noting that current treatments may be sedating or controlled substances [5] - There is strong prescriber interest in IGALMI, with expectations that it could be used in approximately 70% of their patients with schizophrenia and bipolar disorder [5] - Payers anticipate broad formulary coverage for IGALMI, indicating positive feedback on potential inclusion in treatment plans [5] Patient Demand and Advocacy - Patient interviews highlighted a high unmet need for effective at-home treatment options for acute agitation, reinforcing the urgency for IGALMI's availability [6] - Prior research indicated that patients with schizophrenia and bipolar disorder expect to use IGALMI in about 80% of their acute agitation episodes [5] Company Background - BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [16] - The company is focused on re-innovating existing drugs and leveraging big data to identify new therapeutic indications [16]

Core Viewpoint - BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI, aiming to expand its use for the acute treatment of agitation associated with bipolar disorders or schizophrenia in outpatient settings, with potential approval by the end of 2026 [1][3]. Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop innovative medicines in neuroscience [11]. - The company focuses on drug re-innovation, leveraging existing approved drugs and machine learning to identify new therapeutic indications [11]. Product Information - IGALMI (dexmedetomidine) is the first orally dissolving sublingual film approved for treating agitation associated with schizophrenia and bipolar disorders under healthcare supervision [2][5]. - The sNDA submission seeks to allow treatment in outpatient settings without healthcare supervision, addressing a significant unmet medical need [2][3]. Clinical Trial Results - The sNDA is supported by the successful completion of the Phase 3 SERENITY At-Home safety trial, where IGALMI met its primary endpoint of being well-tolerated in the at-home setting [4]. - The safety profile of IGALMI in the trial was consistent with the approved label, indicating its potential for broader use [4]. Market Opportunity - There are approximately 7.3 million individuals in the U.S. diagnosed with schizophrenia or bipolar disorders, with an estimated 57 to 77 million annual agitation episodes occurring [3]. - The company is conducting a market opportunity assessment to evaluate commercialization strategies for IGALMI [3].

Core Insights - BioXcel Therapeutics is highlighted as a promising penny stock due to its late-stage pipeline progress, increasing market potential, and an upcoming FDA milestone, making it a company to watch for 2026 [1] Company Overview - BioXcel Therapeutics is a biopharmaceutical company that utilizes artificial intelligence (AI) and machine learning to discover and develop innovative treatments, particularly in neuroscience [2] - The company's lead product, IGALMI, is an FDA-approved sublingual film formulation of BXCL501 designed for the immediate treatment of severe agitation in individuals with schizophrenia and bipolar disorder [2] Regulatory Developments - BioXcel has conducted a Phase 3 SERENITY At-Home trial with 246 patients to evaluate the safety of BXCL501 in a home-use setting, collecting data on over 2,600 agitation episodes [3] - The trial results showed no discontinuations due to tolerability, no major adverse events related to the drug, and no new safety signals, prompting the company to submit a supplemental New Drug Application (sNDA) to the FDA for at-home use of IGALMI [3] - The company anticipates FDA approval within the year and is preparing for pre-launch and commercial activities [3] Market Potential - BioXcel is advancing its TRANQUILITY In-Care Phase 3 program to address agitation associated with Alzheimer's dementia, having received FDA feedback on the clinical protocol [4] - The company estimates that the at-home agitation market in the U.S. represents between 57 million and 77 million episodes annually, significantly higher than previous estimates of 23 million episodes [5] - If approved, at-home IGALMI could fulfill a substantial unmet need by transitioning treatment from institutional settings to patients' homes, benefiting the patients [5]